Company Overview and News
I can't believe it's been over a month since my last buy was made, but if you have been following my blog for some time, you know at least one buy is coming every calendar month. With one week left in April, I decided to deploy some fresh capital into a market that has been very, very generous as of late in terms of giving us much better buying opportunities in many "name brand" stocks that have been previously deemed untouchable because of low yields, high valuations and relatively speaking, high prices.
On June 30, I will retire for a second time, eight years after my first attempt in 2010. The stock market has been my hobby since 1982. I've always liked dividend stocks and for the past decade I've focused exclusively on dividend stocks. My goal has been to create a third stream of retirement income to complement Social Security and a pension annuity.
MIAMI, April 24, 2018 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) (together with NCL Corporation Ltd., "Norwegian Cruise Line Holdings," "Norwegian" or the "Company") today announced that it has expanded its Board of Directors (the "Board") with the appointment of Ms. Pamela Thomas-Graham as a new independent member, effective April 23, 2018.
The market pundits/experts on CNBC, Bloomberg, Fox and other media networks swing back and forth day to day and sometimes hour to hour on virtually each and every one of their "expert" opinions of the global economy, financial markets and politics. These "knowledgeable experts" are always looking through the rear view mirror at current/past events rather than looking through the windshield projecting the future which should be what they are doing.
Procter & Gamble's US$4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products.
Procter & Gamble Co (NYSE:PG) stock took a hit following its earnings announcement. Although the company beat on both revenue and net income, earnings guidance disappointed Wall Street. Most of its peers in the consumer defensive sector also saw stock price drops on slower-than-expected growth.
Stocks have been gaining of late as earnings season kicks off, but the major equity indexes were indicated to open lower on Thursday. Investors have been rethinking what the nine-year bull market may bring in 2018 and beyond. The trend of buying pullbacks has become more vulnerable to sellers, volatility, and each major news headline versus in 2017. Many investors are finding it hard to decide how they want their assets positioned for the longer term.
The stock market has been crazy lately. It has been a long time since I have seen this many “red” days in the market. But as a dividend growth investor with a long-term investing mindset, markets like these can create some great buying opportunities. This is why I wanted to perform a stock analysis on a Dividend Aristocrat that has traded at a high multiple over the last few years to see if their stock price has fallen to the point where they are potentially considered undervalued.
The Clorox Company (CLX) manufactures and markets consumer and professional products worldwide. It operates in four segments – Cleaning, Household, Lifestyle and International. This dividend aristocrat has paid dividends since 1968 and has increased them each year since 1977.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET